Validating cancer drug targets through chemical genetics

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 251-257

  Burkard, Mark E ^a   Jallepalli, Prasad V ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Inhibitor; Kinase; Mutagenesis; Neoplasm; Resistance

Indexed keywords

B RAF KINASE INHIBITOR; BCR ABL PROTEIN; BEVACIZUMAB; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLAVOPIRIDOL; GEFITINIB; IMATINIB; K RAS PROTEIN; LAPATINIB; NILOTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLO LIKE KINASE 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; CYCLIN DEPENDENT KINASE 7; PROTEIN KINASE; SOMATOMEDIN B; SOMATOMEDIN C;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESISTANCE; CHEMICAL GENETICS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; GENE TRANSLOCATION; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; DRUG DEVELOPMENT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; MITOGENICITY; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 78649455478     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.08.002     Document Type: Review

References (33)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006, 20:1496-1510.
3. Sharma S.V., Fischbach M.A., Haber D.A., Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006, 12:4392s-4395s.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 2004, 101:13306-13311.
5. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
6. Guerin M., Barrois M., Terrier M.J., Spielmann M., Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988, 3:21-31.
7. Wilkinson K., Velloso E.R., Lopes L.F., Lee C., Aster J.C., Shipp M.A., Aguiar R.C. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102:4187-4190.
8. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
9. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
10. Flaherty K., Puzanov I., Sosman J., Kim K., Ribas A., McArthur G., Lee R.J., Grippo J.F., Nolap K., Chapman P. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 2009, 27. Abstract 9000.
11. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell. Biol. 2006, 26:2093-2108.
12. Schmit T.L., Zhong W., Setaluri V., Spiegelman V.S., Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J. Invest. Dermatol. 2009, 129:2843-2853.
13. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
14. Sur S., Pagliarini R., Bunz F., Rago C., Diaz L.A., Kinzler K.W., Vogelstein B., Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl Acad. Sci. USA 2009, 106:3964-3969.
15. Fedorov O., Muller S., Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010, 6:166-169.
16. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
17. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
18. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., Marin D., Nikolova Z., Olavarria E., Silberman S., Schultheis B., Cross N.C., Goldman J.M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl J. Med. 2002, 347:481-487.
19. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 8:219-225.
20. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
21. Forbes S.A., Tang G., Bindal N., Bamford S., Dawson E., Cole C., Kok C.Y., Jia M., Bindal Ewing, Menzies A., Teague J.W., Stratton M.R., Futreal P.A. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010, 38:D652-657.
22. Shogren-Knaak M.A., Alaimo P.J., Shokat K.M. Recent advances in chemical approaches to the study of biological systems. Annu. Rev. Cell Dev. Biol. 2001, 17:405-433.
23. Wong S., McLaughlin J., Cheng D., Zhang C., Shokat K.M., Witte O.N. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl Acad. Sci. USA 2004, 101:17456-17461.
24. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
25. Buzko O., Shokat K.M. A kinase sequence database: sequence alignments and family assignment. Bioinformatics 2002, 18:1274-1275.
26. Schmidt M., Budirahardja Y., Klompmaker R., Medema R.H. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep. 2005, 6:866-872.
27. Du J., Bernasconi P., Clauser K.R., Mani D.R., Finn S.P., Beroukhim R., Burns M., Julian B., Peng X.P., Hieronymus H., Maglathlin R.L., Lewis T.A., Liau L.M., Nghiemphu P., Mellinghoff I.K., Louis D.N., Loda M., Carr S.A., Kung A.L., Golub T.R. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat. Biotechnol. 2009, 27:77-83.
28. Bishop A.C., Ubersax J.A., Petsch D.T., Matheos D.P., Gray N.S., Blethrow J., Shimizu E., Tsien J.Z., Schultz P.G., Rose M.D., Wood J.L., Morgan D.O., Shokat K.M. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000, 407:395-401.
29. Kung C., Kenski D.M., Dickerson S.H., Howson R.W., Kuyper L.F., Madhani H.D., Shokat K.M. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl Acad. Sci. USA 2005, 102:3587-3592.
30. Wang H., Shimizu E., Tang Y.P., Cho M., Kyin M., Zuo W., Robinson D.A., Alaimo P.J., Zhang C., Morimoto H., Zhuo M., Feng R., Shokat K.M., Tsien J.Z. Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc. Natl Acad. Sci. USA 2003, 100:4287-4292.
31. Larochelle S., Merrick K.A., Terret M.E., Wohlbold L., Barboza N.M., Zhang C., Shokat K.M., Jallepalli P.V., Fisher R.P. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 2007, 25:839-850.
32. Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., Jallepalli P.V. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 2009, 7:e1000111.
33. Burkard M.E., Randall C.L., Larochelle S., Zhang C., Shokat K.M., Fisher R.P., Jallepalli P.V. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc. Natl Acad. Sci. USA 2007, 104:4383-4388.